MaaT Pharma S.A.
MAAT.PA
Euronext Paris2.66
EUR
-0.08
- -
MaaT Pharma S.A.
MAAT.PA
(Euronext Paris)
Recent
price
2.66
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- MaaT Pharma S.A. is a late-stage clinical biotechnology company specializing in the development and commercialization of microbiome-driven therapies aimed at modulating the immune system to improve survival in cancer patients, with a particular focus on hemato-oncology and oncology indications. The company develops high-diversity, standardized drug candidates using proprietary pooling and microbial co-cultivation technologies, creating Microbiome Ecosystem Therapies™ (MET) designed to treat moderate to severe dysbiosis in patients with severe oncology diseases. Its product portfolio includes MaaT013 (Xervyteg®), an immunomodulatory drug candidate based on intestinal microbiota currently undergoing Phase 3 clinical evaluation for acute Graft-versus-Host Disease (aGvHD) following allogeneic hematopoietic stem cell transplantation, and MaaT033, a second therapeutic candidate in Phase 2b development aimed at improving survival in patients receiving bone marrow transplants. The company also advances next-generation MET-C synthetic microbiome products for improving immunotherapy responses in solid tumors. MaaT Pharma is headquartered in Lyon, France, and was founded in 2014. It operates globally with significant clinical and commercial activities focused in Europe and plans regulatory expansion into the U.S. The company targets healthcare providers in oncology, rare diseases, and immunotherapy markets. MaaT Pharma has been listed on Euronext Paris under the ticker MAAT since 2021. In recent major developments within the last two years, MaaT Pharma successfully completed a global capital increase of approximately €9.1 million in November 2025 to fund clinical development and regulatory preparations. The company is advancing the commercial launch of Xervyteg® in Europe in collaboration with Clinigen, a specialty pharmaceutical services provider that secured exclusive commercialization rights for the product across Europe, aiming for potential marketing authorization around mid-2026. Furthermore, MaaT Pharma secured a €37.5 million venture debt facility from the European Investment Bank in mid-2025 to support late-stage clinical programs and expand pipeline development. The company is preparing regulatory submissions and pivotal studies with the U.S. FDA for potential expedited approval and launch of Xervyteg® in the U.S. Additionally, MaaT Pharma is expanding its product pipeline with immunotherapy combination trials in solid tumors and continues to develop synthetic microbiome therapies to enhance immunotherapy efficacy in oncology. This strategic expansion, capital strengthening, and commercialization partnership position MaaT Pharma as an innovative leader in microbiome-based immunomodulation therapies targeting high unmet needs in oncology and hematology.